Methadone is a Schedule II controlled substance under the federal Controlled Substances Act. That places it in the same category as oxycodone, fentanyl, Adderall, and methamphetamine. Schedule II is the most restrictive classification for drugs that have accepted medical uses, reflecting a high potential for abuse and the risk of severe physical or psychological dependence.
What Schedule II Means in Practice
The DEA organizes controlled substances into five schedules. Schedule I includes drugs with no accepted medical use (like heroin), while Schedules II through V represent decreasing levels of abuse potential. Schedule II sits at the top of the medically useful tiers, meaning methadone is recognized as having legitimate treatment value but carries serious risks.
For you as a patient, the Schedule II classification translates into tighter rules around how methadone is prescribed, dispensed, and stored. Pharmacies must keep Schedule II prescriptions in a separate file from all other medications. Providers and clinics that handle methadone are required to maintain detailed inventories and make those records available for federal inspection. Refills on a standard Schedule II prescription are not allowed; you need a new prescription each time.
Why Methadone Is Classified This Way
Methadone is a full opioid agonist, meaning it activates the same brain receptors as heroin, morphine, and other opioids. It produces pain relief, sedation, and, at higher doses, euphoria. What distinguishes it from shorter-acting opioids is its unusually long half-life. It stays active in the body for much longer than most opioids, which is why it works well for sustained pain control and for preventing withdrawal symptoms in people with opioid use disorder. But that same long duration increases the risk of dangerous buildup in the body, especially when someone is new to the drug or takes too much.
Its full agonist activity is also why federal agencies treat it differently from buprenorphine, the other major medication used for opioid use disorder. Buprenorphine is a partial agonist (it activates opioid receptors less intensely) and is classified as Schedule III, one tier lower. That difference in scheduling has major consequences for how each drug reaches patients.
Methadone for Opioid Use Disorder
The FDA approves methadone for two distinct purposes: pain management and the treatment of opioid use disorder (OUD). The rules for each use are very different.
When methadone is used for opioid use disorder, it can only be dispensed through federally certified Opioid Treatment Programs, commonly called methadone clinics. These programs must hold certification from SAMHSA and DEA registration. A regular doctor’s office or retail pharmacy cannot dispense methadone for addiction treatment the way they can with buprenorphine. This is the single biggest practical effect of methadone’s Schedule II status combined with federal OTP regulations: most patients must physically go to a clinic, often daily, to receive their dose.
To be admitted to an OTP, you need to meet diagnostic criteria for moderate to severe opioid use disorder, or be in remission but at high risk for relapse or overdose. A healthcare practitioner must confirm your diagnosis, explain the treatment, and obtain your informed consent. Patients under 18 generally need written consent from a parent or legal guardian.
Methadone for Pain Management
When prescribed strictly for pain, methadone follows the same dispensing rules as other Schedule II painkillers. A licensed prescriber can write a prescription, and a regular pharmacy can fill it. There is no requirement to visit a specialized clinic. The key distinction is the stated purpose: the moment methadone is being used to treat opioid addiction rather than pain, OTP rules kick in.
Hospitals and long-term care facilities are an exception. If you’re admitted for a medical condition unrelated to addiction but happen to need methadone to manage your opioid use disorder during your stay, the facility can administer it without being a certified OTP.
Recent Changes to Access Rules
A 2024 federal rule expanded how patients can start methadone treatment for opioid use disorder. OTPs are now allowed to evaluate new patients through audio-visual telehealth rather than requiring an in-person visit before the first dose. The rule does not extend to audio-only calls, because methadone’s higher sedation risk compared to buprenorphine makes a visual assessment important. The rule also does not allow methadone to be prescribed through a telehealth visit and mailed to a patient; it must still be dispensed at a clinic or authorized medication unit.
Separately, the DEA announced telemedicine rules that allow certain board-certified specialists (psychiatrists, hospice physicians, and others) to prescribe Schedule II medications through telehealth under a special registration. For most patients seeking methadone for opioid use disorder, though, the OTP clinic model remains the primary pathway.
How Methadone Compares to Other OUD Medications
Three FDA-approved medications treat opioid use disorder: methadone, buprenorphine, and naltrexone. Their scheduling reflects their abuse potential.
- Methadone (Schedule II): Full opioid agonist. Dispensed almost exclusively through certified clinics for addiction treatment. Highest level of regulatory oversight among the three.
- Buprenorphine (Schedule III): Partial opioid agonist. Can be prescribed by qualified providers in a regular office setting and filled at retail pharmacies. Lower abuse ceiling due to its partial agonist properties.
- Naltrexone (not scheduled): An opioid blocker, not an opioid. No abuse potential, no special dispensing requirements.
The practical gap between methadone and buprenorphine is significant. Buprenorphine’s Schedule III status means fewer barriers: standard prescriptions, pharmacy pickup, and broader telehealth options. Methadone’s Schedule II classification, combined with OTP requirements, means more clinic visits and less flexibility, particularly early in treatment before a patient earns take-home doses. For some patients, methadone’s stronger opioid activity is clinically necessary, which is why it remains a cornerstone of addiction treatment despite the added logistical burden.